U.S. Department of Health and Human Services
Jürgen Wess
 

 Contact Info

 
Tel: 301-402-3589
Email: jurgenw@helix.nih.gov
 

 Select Experience

 
  • ChiefMolecular Signaling Section, Laboratory of Biological Chemistry, NIDDK, NIH1998
  • HeadG Protein-Coupled Receptor Unit, NIDDK, NIH1993-1997
  • HeadG Protein-Coupled Receptor Unit, NINDS, NIH1991-1993
  • Postdoctoral FellowJoint Appointment at NIMH and NINDS, NIH1988-1991
  • Ph.D.Johann Wolfgang-Goethe University1987
 

 Related Links

 

    Jürgen Wess, Ph.D.

    Senior Investigator, Laboratory of Bioorganic ChemistryMolecular Signaling Section
    Specialties
    • Cell Biology/Cell Signaling
    • Molecular Biology/Biochemistry
    • Molecular Pharmacology/Toxicology

    Research Summary

    Research Goal

    The ultimate goal of this work is to identify novel drug targets for the more effective treatment of various human diseases, including type 2 diabetes and obesity.

    Current Research

    My laboratory pursues the following two major lines of work.

    GPCRs - Molecular Basis of Activation and Function

    One major focus of my group is to understand how GPCRs function at the molecular level. GPCRs, one of the largest protein families found in nature, are cell-surface receptors that mediate the functions of an extraordinarily large number of extracellular ligands (neurotransmitters, hormones, etc.). The human genome contains approximately 800 distinct GPCR genes, corresponding to 3-4 percent of all human genes. Strikingly, 30-40 percent of drugs in current clinical use act on specific GPCRs. Understanding how GPCRs function at the molecular level is therefore of considerable therapeutic relevance. My lab uses different molecular, genetic, and biochemical strategies to address the following fundamental questions regarding the structure and function of these receptors: (1) How do GPCRs recognize and activate G proteins? (2) Which conformational changes do activating ligands induce in the receptor protein? (3) What is the structural basis and functional relevance of GPCR dimerization? My lab is also engaged in efforts, in collaboration with Dr. Brian Kobilka’s lab, to obtain high-resolution X-ray structures for members of the muscarinic receptor family of GPCRs. These studies should eventually lead to novel therapeutic approaches aimed at modulating the function of specific GPCRs.

    Generation and Analysis of GPCR Mutant Mice to Explore GPCR Signaling and Physiology

    Many of the important physiological functions of the neurotransmitter acetylcholine are caused by the interaction of acetylcholine with a group of GPCRs referred to as muscarinic receptors. Molecular cloning studies have revealed the existence of five molecularly distinct muscarinic receptor subtypes referred to as M1-M5. The M1-M5 receptors are abundantly expressed in most cells and tissues and are critically involved in regulating many fundamental physiological processes including, for example, the regulation of body weight and food intake, the release of insulin from pancreatic beta cells, and many key functions of the CNS including most cognitive processes. To elucidate the physiological roles of the individual muscarinic receptor subtypes, we are using gene-targeting techniques, including Cre/loxP technology, to generate mouse lines lacking functional M1-M5 muscarinic receptors, either throughout the body or only in certain tissues or cell types. Current phenotyping studies are focusing on the potential roles of the different muscarinic receptor subtypes in regulating energy and glucose homeostasis in various peripheral and central tissues.

    In a related line of work, we are generating and analyzing transgenic mice expressing mutationally modified mutant GPCRs in specific, metabolically relevant cell types such pancreatic beta-cells, hepatocytes, myocytes, and certain subsets of hypothalamic neurons. These designer GPCRs are unable to bind endogenous ligands but can be efficiently activated by an exogenously administered drug (clozapine-N-oxide; CNO). This drug is otherwise pharmacologically inert. For this work, we are using several CNO-sensitive designer GPCRs that differ in their G protein-coupling properties (Gq, Gs, Gi, etc.) or which preferentially activate arrestin-dependent signaling pathways. This novel approach makes it possible to selectively activate, in vivo, distinct GPCR signaling pathways in a cell type-specific and drug-dependent fashion. These studies, which are being carried out in collaboration with the NIDDK metabolic phenotyping, transgenic, and mouse knockout core facilities, are likely to identify novel therapeutic targets for the treatment of various pathophysiological conditions including type 2 diabetes and obesity.​

    Applying our Research

    Type 2 diabetes and obesity have emerged as major threats to human health in the 21st century. It is likely that the proposed studies will identify novel biological targets for the treatment of these and related pathophysiological conditions. Moreover, a better understanding of GPCR structure and function should lead to new strategies aimed at improving the pharmacotherapy of many important human diseases.

    Need for Further Study

    Areas in this field that require further study include GPCR structure and function and the physiological and pathophysiological roles of distinct GPCRs and GPCR signaling pathways in specific cell types in vivo.